Reichart, Daniel
Newby, Gregory A.
Wakimoto, Hiroko http://orcid.org/0000-0003-0225-6424
Lun, Mingyue
Gorham, Joshua M. http://orcid.org/0000-0001-5969-4690
Curran, Justin J.
Raguram, Aditya http://orcid.org/0000-0002-5749-7308
DeLaughter, Daniel M.
Conner, David A.
Marsiglia, JĂșlia D. C.
Kohli, Sajeev
Chmatal, Lukas
Page, David C.
Zabaleta, Nerea http://orcid.org/0000-0001-8093-4695
Vandenberghe, Luk
Liu, David R.
Seidman, Jonathan G. http://orcid.org/0000-0002-9082-3566
Seidman, Christine http://orcid.org/0000-0001-6380-1209
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (HL080494, HL084553, U01 AI142756, RM1 HG009490, R35 GM118062, HL080494, HL084553)
Deutsche Forschungsgemeinschaft (N/A)
Helen Hay Whitney Foundation
National Science Foundation Graduate Research Award
Article History
Received: 6 July 2022
Accepted: 16 December 2022
First Online: 16 February 2023
Competing interests
: L.H.V. holds equity and serves on the Board of Directors for Affinia Therapeutics and Ciendias Bio, where he is employed, and holds equity in Akouos. He has licensed technology to Affinia, Akouos and Novartis. D.R.L. is a consultant and equity owner of Beam Therapeutics, Prime Medicine, Pairwise Plants and Chroma Medicine, companies that use genome editing or genome engineering. J.G.S. and C.E.S are founders of Myokardia (a Bristol Myers Squibb subsidiary) and are consultants for Maze and BridgeBio. C.E.S serves on the Merck Board of Directors and the Burroughs Wellcome Fund. None of these companies had any input into the design, execution, analyses or writing of this manuscript. Other authors declare no competing interests.